The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications

American Journal of Pathology

Volumn 180, Issue 2, 2012, Pages 432-442

  Horvth, Bla ^a,b   Mukhopadhyay, Partha ^a   Hask, Gyrgy ^c   Pacher, Pl ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; DELTA9 TETRAHYDROCANNABIVARIN; DRONABINOL; ENDOCANNABINOID; INSULIN; METFORMIN; RIMONABANT; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HEART INFARCTION; HUMAN; MENTAL DISEASE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

CANNABINOIDS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; OXIDATIVE STRESS; RECEPTORS, CANNABINOID; TETRAHYDROCANNABINOL;

EID: 84856010479     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.11.003     Document Type: Review

References (104)

1. P. Pacher, S. Batkai, G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol Rev 58 2006 389 462
2. R.G. Pertwee Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists Curr Med Chem 17 2010 1360 1381
3. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, M.R. Elphick, P.J. Greasley, H.S. Hansen, G. Kunos, K. Mackie, R. Mechoulam, R.A. Ross International Union of Basic and Clinical Pharmacology LXXIX Cannabinoid receptors and their ligands: beyond CB and CB Pharmacol Rev 62 2010 588 631
4. P. Pacher, R. Mechoulam Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50 2011 193 211
5. V. Di Marzo, M. Bifulco, L. De Petrocellis The endocannabinoid system and its therapeutic exploitation Nat Rev Drug Discov 3 2004 771 784
6. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
7. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, A.R. Schatz, A. Gopher, S. Almog, B.R. Martin, D.R. Compton Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem Pharmacol 50 1995 83 90
8. S. Petrosino, V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr Opin Investig Drugs 11 2010 51 62
9. A.A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, R. Mechoulam Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb Trends Pharmacol Sci 30 2009 515 527
10. L. Weiss, M. Zeira, S. Reich, M. Har-Noy, R. Mechoulam, S. Slavin, R. Gallily Cannabidiol lowers incidence of diabetes in non-obese diabetic mice Autoimmunity 39 2006 143 151
11. L. Weiss, M. Zeira, S. Reich, S. Slavin, I. Raz, R. Mechoulam, R. Gallily Cannabidiol arrests onset of autoimmune diabetes in NOD mice Neuropharmacology 54 2008 244 249
12. A.B. El-Remessy, M. Al-Shabrawey, Y. Khalifa, N.T. Tsai, R.B. Caldwell, G.I. Liou Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes Am J Pathol 168 2006 235 244
13. M. Rajesh, P. Mukhopadhyay, S. Batkai, G. Hasko, L. Liaudet, V.R. Drel, I.G. Obrosova, P. Pacher Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption Am J Physiol Heart Circ Physiol 293 2007 H610 H619
14. M. Rajesh, P. Mukhopadhyay, S. Batkai, V. Patel, K. Saito, S. Matsumoto, Y. Kashiwaya, B. Horvath, B. Mukhopadhyay, L. Becker, G. Hasko, L. Liaudet, D.A. Wink, A. Veves, R. Mechoulam, P. Pacher Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy J Am Coll Cardiol 56 2010 2115 2125
15. G.W. Booz Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress Free Radic Biol Med 51 2011 1054 1061
16. D. Bolognini, B. Costa, S. Maione, F. Comelli, P. Marini, V. Di Marzo, D. Parolaro, R.A. Ross, L.A. Gauson, M.G. Cascio, R.G. Pertwee The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice Br J Pharmacol 160 2010 677 687
17. S. Batkai, P. Mukhopadhyay, B. Horvath, M. Rajesh, R.Y. Gao, A. Mahadevan, M. Amere, N. Battista, A.H. Lichtman, L.A. Gauson, M. Maccarrone, R.G. Pertwee, P. Pacher Delta(8)-Tetrahydrocannabivarin protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress and inflammatory response involving CB(2) receptors Br J Pharmacol 2011 10.1111/j.1476-5381.2011. 01410.x
18. Centers for Disease Control and Prevention National Diabetes Fact Sheet 2011 Centers for Disease Control and Prevention Atlanta
19. S. van Dieren, J.W. Beulens, Y.T. van der Schouw, D.E. Grobbee, B. Neal The global burden of diabetes and its complications: an emerging pandemic Eur J Cardiovasc Prev Rehabil 17 suppl 1 2010 S3 S8
20. F. Giacco, M. Brownlee Oxidative stress and diabetic complications Circ Res 107 2010 1058 1070
21. P. Pacher, J.S. Beckman, L. Liaudet Nitric oxide and peroxynitrite in health and disease Physiol Rev 87 2007 315 424
22. V. Di Marzo, S.K. Goparaju, L. Wang, J. Liu, S. Batkai, Z. Jarai, F. Fezza, G.I. Miura, R.D. Palmiter, T. Sugiura, G. Kunos Leptin-regulated endocannabinoids are involved in maintaining food intake Nature 410 2001 822 825
23. S. Engeli, J. Bohnke, M. Feldpausch, K. Gorzelniak, J. Janke, S. Batkai, P. Pacher, J. Harvey-White, F.C. Luft, A.M. Sharma, J. Jordan Activation of the peripheral endocannabinoid system in human obesity Diabetes 54 2005 2838 2843
24. V. Di Marzo The endocannabinoid system in obesity and type 2 diabetes Diabetologia 51 2008 1356 1367
25. G. Kunos, J. Tam The case for peripheral CB(1) receptor blockade in the treatment of visceral obesity and its cardiometabolic complications Br J Pharmacol 163 2011 1423 1431
26. J.P. Despres, A. Golay, L. Sjostrom Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia N Engl J Med 353 2005 2121 2134
27. L.F. Van Gaal, A.M. Rissanen, A.J. Scheen, O. Ziegler, S. Rossner Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365 2005 1389 1397
28. F.X. Pi-Sunyer, L.J. Aronne, H.M. Heshmati, J. Devin, J. Rosenstock Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: rIO-North America: a randomized controlled trial JAMA 295 2006 761 775
29. E.J. Topol, M.G. Bousser, K.A. Fox, M.A. Creager, J.P. Despres, J.D. Easton, C.W. Hamm, G. Montalescot, P.G. Steg, T.A. Pearson, E. Cohen, C. Gaudin, B. Job, J.H. Murphy, D.L. Bhatt Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial Lancet 376 2010 517 523
30. J. Tam, V.K. Vemuri, J. Liu, S. Batkai, B. Mukhopadhyay, G. Godlewski, D. Osei-Hyiaman, S. Ohnuma, S.V. Ambudkar, J. Pickel, A. Makriyannis, G. Kunos Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity J Clin Invest 120 2010 2953 2966
31. P. Juan-Pico, E. Fuentes, F.J. Bermudez-Silva, F. Javier Diaz-Molina, C. Ripoll, F. Rodriguez de Fonseca, A. Nadal Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell Cell Calcium 39 2006 155 162
32. F.J. Bermudez-Silva, I. Sanchez-Vera, J. Suarez, A. Serrano, E. Fuentes, P. Juan-Pico, A. Nadal, F. Rodriguez de Fonseca Role of cannabinoid CB2 receptors in glucose homeostasis in rats Eur J Pharmacol 565 2007 207 211
33. K.M. Starowicz, L. Cristino, I. Matias, R. Capasso, A. Racioppi, A.A. Izzo, V. Di Marzo Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet Obesity (Silver Spring) 16 2008 553 565
34. C. Li, J.E. Bowe, P.M. Jones, S.J. Persaud Expression and function of cannabinoid receptors in mouse islets Islets 2 2010 293 302
35. W. Kim, M.E. Doyle, Z. Liu, Q. Lao, Y.-K. Shin, O.D. Carlson, H.S. Kim, S. Thomas, J.K. Napora, E.K. Lee, R. Moaddel, Y. Wang, S. Maudsley, B. Martin, R.N. Kulkarni, J.M. Egan Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells Diabetes 60 2011 1198 1209
36. W.G. Tharp, Y.H. Lee, R.L. Maple, R.E. Pratley The cannabinoid CB1 receptor is expressed in pancreatic delta-cells Biochem Biophys Res Commun 372 2008 595 600
37. A. Vilches-Flores, N.L. Delgado-Buenrostro, G. Navarrete-Vazquez, R. Villalobos-Molina CB1 cannabinoid receptor expression is regulated by glucose and feeding in rat pancreatic islets Regul Pept 163 2010 81 87
38. F.J. Bermudez-Silva, J. Suarez, E. Baixeras, N. Cobo, D. Bautista, A.L. Cuesta-Munoz, E. Fuentes, P. Juan-Pico, M.J. Castro, G. Milman, R. Mechoulam, A. Nadal, F. Rodriguez de Fonseca Presence of functional cannabinoid receptors in human endocrine pancreas Diabetologia 51 2008 476 487
39. I. Matias, M.P. Gonthier, P. Orlando, V. Martiadis, L. De Petrocellis, C. Cervino, S. Petrosino, L. Hoareau, F. Festy, R. Pasquali, R. Roche, M. Maj, U. Pagotto, P. Monteleone, V. Di Marzo Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia J Clin Endocrinol Metab 91 2006 3171 3180
40. C. Li, P.M. Jones, S.J. Persaud Cannabinoid receptors are coupled to stimulation of insulin secretion from mouse MIN6 beta-cells Cell Physiol Biochem 26 2010 187 196
41. M. Nakata, T. Yada Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors Regul Pept 145 2008 49 53
42. A.J. Scheen, N. Finer, P. Hollander, M.D. Jensen, L.F. Van Gaal Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study Lancet 368 2006 1660 1672
43. J. Rosenstock, P. Hollander, S. Chevalier, A. Iranmanesh SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes Diabetes Care 31 2008 2169 2176
44. P.A. Hollander, A. Amod, L.E. Litwak, U. Chaudhari Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial Diabetes Care 33 2010 605 607
45. G. Annuzzi, F. Piscitelli, L. Di Marino, L. Patti, R. Giacco, G. Costabile, L. Bozzetto, G. Riccardi, R. Verde, S. Petrosino, A.A. Rivellese, V. Di Marzo Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients Lipids Health Dis [Internet] 9 2010 43 http://www.lipidworld.com/content/9/1/43 10.1186/1476-511X-9-43 [cited 2011 December 21]
46. T.W. Klein Cannabinoid-based drugs as anti-inflammatory therapeutics Nat Rev Immunol 5 2005 400 411
47. X. Li, N.E. Kaminski, L.J. Fischer Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes Int Immunopharmacol 1 2001 699 712
48. H.C. Gerstein, M.E. Miller, S. Genuth, F. Ismail-Beigi, J.B. Buse, D.C. Goff Jr., J.L. Probstfield, W.C. Cushman, H.N. Ginsberg, J.T. Bigger, R.H. Grimm Jr., R.P. Byington, Y.D. Rosenberg, W.T. Friedewald Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med 364 2011 818 828
49. P. Pacher, S. Steffens The emerging role of the endocannabinoid system in cardiovascular disease Semin Immunopathol 31 2009 63 77
50. M. Rajesh, P. Mukhopadhyay, G. Hasko, L. Liaudet, K. Mackie, P. Pacher Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells Br J Pharmacol 160 2010 688 700
51. V. Tiyerili, S. Zimmer, S. Jung, K. Wassmann, C.P. Naehle, D. Lutjohann, A. Zimmer, G. Nickenig, S. Wassmann CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function Basic Res Cardiol 105 2010 465 477
52. M. Rajesh, P. Mukhopadhyay, S. Batkai, G. Hasko, L. Liaudet, J.W. Huffman, A. Csiszar, Z. Ungvari, K. Mackie, S. Chatterjee, P. Pacher CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion Am J Physiol Heart Circ Physiol 293 2007 H2210 H2218
53. K.H. Han, S. Lim, J. Ryu, C.W. Lee, Y. Kim, J.H. Kang, S.S. Kang, Y.K. Ahn, C.S. Park, J.J. Kim CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages Cardiovasc Res 84 2009 378 386
54. P. Mukhopadhyay, B. Horvath, M. Rajesh, S. Matsumoto, K. Saito, S. Batkai, V. Patel, G. Tanchian, R.Y. Gao, B.F. Cravatt, G. Hasko, P. Pacher Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury Free Radic Biol Med 50 2011 179 195
55. M. Rajesh, P. Mukhopadhyay, G. Hasko, P. Pacher Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation Biochem Biophys Res Commun 377 2008 1248 1252
56. M. Rajesh, P. Mukhopadhyay, G. Hasko, J.W. Huffman, K. Mackie, P. Pacher CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration Br J Pharmacol 153 2008 347 357
57. S. Steffens, N.R. Veillard, C. Arnaud, G. Pelli, F. Burger, C. Staub, M. Karsak, A. Zimmer, J.L. Frossard, F. Mach Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice Nature 434 2005 782 786
58. F. Dol-Gleizes, R. Paumelle, V. Visentin, A.M. Mares, P. Desitter, N. Hennuyer, A. Gilde, B. Staels, P. Schaeffer, F. Bono Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice Arterioscler Thromb Vasc Biol 29 2009 12 18
59. K. Sugamura, S. Sugiyama, T. Nozaki, Y. Matsuzawa, Y. Izumiya, K. Miyata, M. Nakayama, K. Kaikita, T. Obata, M. Takeya, H. Ogawa Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages Circulation 119 2009 28 36
60. C. Mingorance, M. Alvarez de Sotomayor, F.J. Jimenez-Palacios, M. Callejon Mochon, C. Casto, E. Marhuenda, M.D. Herrera Effects of chronic treatment with the CB1 antagonist, rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats Obesity (Silver Spring) 17 2009 1340 1347
61. C. Mingorance, M.A. de Sotomayor, E. Marhuenda, M.D. Herrera Chronic treatment with the cannabinoid 1 antagonist rimonabant altered vasoactive cyclo-oxygenase-derived products on arteries from obese Zucker rats J Cardiovasc Pharmacol 56 2010 560 569
62. J.C. Russell, S.E. Kelly, A. Diane, Y. Wang, R. Mangat, S. Novak, D.F. Vine, S.D. Proctor Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR: LA-cp rat model of prediabetic metabolic syndrome Am J Physiol Gastrointest Liver Physiol 299 2010 G507 G516
63. S.E. Nissen, S.J. Nicholls, K. Wolski, J. Rodes-Cabau, C.P. Cannon, J.E. Deanfield, J.P. Despres, J.J. Kastelein, S.R. Steinhubl, S. Kapadia, M. Yasin, W. Ruzyllo, C. Gaudin, B. Job, B. Hu, D.L. Bhatt, A.M. Lincoff, E.M. Tuzcu Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial JAMA 299 2008 1547 1560
64. O. Asghar, A. Al-Sunni, K. Khavandi, A. Khavandi, S. Withers, A. Greenstein, A.M. Heagerty, R.A. Malik Diabetic cardiomyopathy Clin Sci (Lond) 116 2009 741 760
65. S. Boudina, E.D. Abel Diabetic cardiomyopathy, causes and effects Rev Endocr Metab Disord 11 2010 31 39
66. P. Mukhopadhyay, S. Batkai, M. Rajesh, N. Czifra, J. Harvey-White, G. Hasko, Z. Zsengeller, N.P. Gerard, L. Liaudet, G. Kunos, P. Pacher Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity J Am Coll Cardiol 50 2007 528 536
67. P. Mukhopadhyay, M. Rajesh, S. Batkai, V. Patel, Y. Kashiwaya, L. Liaudet, O.V. Evgenov, K. Mackie, G. Hasko, P. Pacher CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes Cardiovasc Res 85 2010 773 784
68. S.Y. Lim, S.M. Davidson, D.M. Yellon, C.C. Smith The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction Basic Res Cardiol 104 2009 781 792
69. F. Montecucco, S. Lenglet, V. Braunersreuther, F. Burger, G. Pelli, M. Bertolotto, F. Mach, S. Steffens CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion J Mol Cell Cardiol 46 2009 612 620
70. N. Kashihara, Y. Haruna, V.K. Kondeti, Y.S. Kanwar Oxidative stress in diabetic nephropathy Curr Med Chem 17 2010 4256 4269
71. D.G. Deutsch, M.S. Goligorsky, P.C. Schmid, R.J. Krebsbach, H.H. Schmid, S.K. Das, S.K. Dey, G. Arreaza, C. Thorup, G. Stefano, L.C. Moore Production and physiological actions of anandamide in the vasculature of the rat kidney J Clin Invest 100 1997 1538 1546
72. P. Janiak, B. Poirier, J.P. Bidouard, C. Cadrouvele, F. Pierre, L. Gouraud, I. Barbosa, J. Dedio, J.P. Maffrand, G. Le Fur, S. O'Connor, J.M. Herbert Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats Kidney Int 72 2007 1345 1357
73. P. Mukhopadhyay, H. Pan, M. Rajesh, S. Batkai, V. Patel, J. Harvey-White, B. Mukhopadhyay, G. Hasko, B. Gao, K. Mackie, P. Pacher CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model Br J Pharmacol 160 2010 657 668
74. P. Mukhopadhyay, M. Rajesh, H. Pan, V. Patel, B. Mukhopadhyay, S. Batkai, B. Gao, G. Hasko, P. Pacher Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy Free Radic Biol Med 48 2010 457 467
75. H. Pan, P. Mukhopadhyay, M. Rajesh, V. Patel, B. Mukhopadhyay, B. Gao, G. Hasko, P. Pacher Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death J Pharmacol Exp Ther 328 2009 708 714
76. F. Barutta, A. Corbelli, R. Mastrocola, R. Gambino, V. Di Marzo, S. Pinach, M.P. Rastaldi, P.C. Perin, G. Gruden Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy Diabetes 59 2010 1046 1054
77. F. Barutta, F. Piscitelli, S. Pinach, G. Bruno, R. Gambino, M.P. Rastaldi, G. Salvidio, V. Di Marzo, P. Cavallo Perin, G. Gruden Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy Diabetes 60 2011 2386 2396
78. K.A. Jenkin, A.J. McAinch, E. Grinfeld, D.H. Hryciw Role for cannabinoid receptors in human proximal tubular hypertrophy Cell Physiol Biochem 26 2010 879 886
79. J.C. Lim, S.K. Lim, H.J. Han, S.H. Park Cannabinoid receptor 1 mediates palmitic acid-induced apoptosis via endoplasmic reticulum stress in human renal proximal tubular cells J Cell Physiol 225 2010 654 663
80. J.C. Lim, S.K. Lim, M.J. Park, G.Y. Kim, H.J. Han, S.H. Park Cannabinoid receptor 1 mediates high glucose-induced apoptosis via endoplasmic reticulum stress in primary cultured rat mesangial cells Am J Physiol Renal Physiol 301 2011 F179 F188
81. N. Cheung, P. Mitchell, T.Y. Wong Diabetic retinopathy Lancet 376 2010 124 136
82. T. Bisogno, I. Delton-Vandenbroucke, A. Milone, M. Lagarde, V. Di Marzo Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina Arch Biochem Biophys 370 1999 300 307
83. S. Yazulla Endocannabinoids in the retina: from marijuana to neuroprotection Prog Retin Eye Res 27 2008 501 526
84. I. Matias, J.W. Wang, A.S. Moriello, A. Nieves, D.F. Woodward, V. Di Marzo Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration Prostaglandins Leukot Essent Fatty Acids 75 2006 413 418
85. A.B. El-Remessy, M. Rajesh, P. Mukhopadhyay, B. Horvath, V. Patel, M.M. Al-Gayyar, B.A. Pillai, P. Pacher Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line Diabetologia 54 2011 1567 1578
86. S.K. Lim, M.J. Park, J.C. Lim, J.C. Kim, H.J. Han, G.Y. Kim, B.F. Cravatt, C.H. Woo, S.J. Ma, K.C. Yoon, S.H. Park Hyperglycemia induces apoptosis via CB(1) activation through the decrease of FAAH 1 in retina pigment epithelial cells J Cell Physiol 227 2012 569 577
87. A.B. El-Remessy, Y. Khalifa, S. Ola, A.S. Ibrahim, G.I. Liou Cannabidiol protects retinal neurons by preserving glutamine synthetase activity in diabetes Mol Vis 16 2010 1487 1495
88. S. Tesfaye, A.J. Boulton, P.J. Dyck, R. Freeman, M. Horowitz, P. Kempler, G. Lauria, R.A. Malik, V. Spallone, A. Vinik, L. Bernardi, P. Valensi Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments Diabetes Care 33 2010 2285 2293
89. I.G. Obrosova Diabetes and the peripheral nerve Biochim Biophys Acta 1792 2009 931 940
90. A.G. Hohmann, R.L. Suplita 2nd Endocannabinoid mechanisms of pain modulation AAPS J 8 2006 E693 E708
91. N. Agarwal, P. Pacher, I. Tegeder, F. Amaya, C.E. Constantin, G.J. Brenner, T. Rubino, C.W. Michalski, G. Marsicano, K. Monory, K. Mackie, C. Marian, S. Batkai, D. Parolaro, M.J. Fischer, P. Reeh, G. Kunos, M. Kress, B. Lutz, C.J. Woolf, R. Kuner Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors Nat Neurosci 10 2007 870 879
92. M. Karst, S. Wippermann, J. Ahrens Role of cannabinoids in the treatment of pain and (painful) spasticity Drugs 70 2010 2409 2438
93. H.C. Ellington, M.A. Cotter, N.E. Cameron, R.A. Ross The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats Neuropharmacology 42 2002 966 975
94. A. Ulugol, H.C. Karadag, Y. Ipci, M. Tamer, I. Dokmeci The effect of WIN 55,2122, a cannabinoid agonist, on tactile allodynia in diabetic rats Neurosci Lett 371 2004 167 170
95. C.C. Toth, N.M. Jedrzejewski, C.L. Ellis, W.H. Frey 2nd Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain Mol Pain 6 2010 16
96. J.L. Saez-Cassanelli, G.H. Fontanella, J.M. Delgado-Garcia, A.M. Carrion Functional blockage of the cannabinoid receptor type 1 evokes a kappa-opiate-dependent analgesia J Neurochem 103 2007 2629 2639
97. F. Zhang, S. Hong, V. Stone, P.J. Smith Expression of cannabinoid CB1 receptors in models of diabetic neuropathy J Pharmacol Exp Ther 323 2007 508 515
98. F. Zhang, S.C. Challapalli, P.J. Smith Cannabinoid CB(1) receptor activation stimulates neurite outgrowth and inhibits capsaicin-induced Ca(2+) influx in an in vitro model of diabetic neuropathy Neuropharmacology 57 2009 88 96
99. Y. Dagon, Y. Avraham, G. Link, O. Zolotarev, R. Mechoulam, E.M. Berry The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells Neurobiol Dis 27 2007 174 181
100. F. Comelli, I. Bettoni, A. Colombo, P. Fumagalli, G. Giagnoni, B. Costa Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice Eur J Pharmacol 637 2010 62 69
101. W.J. Liu, H.Y. Jin, J.H. Park, H.S. Baek, T.S. Park Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat Eur J Pharmacol 637 2010 70 76
102. B. Fioravanti, M. De Felice, C.L. Stucky, K.A. Medler, M.C. Luo, L.R. Gardell, M. Ibrahim, T.P. Malan Jr., H.I. Yamamura, M.H. Ossipov, T. King, J. Lai, F. Porreca, T.W. Vanderah Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists J Neurosci 28 2008 11593 11602
103. D. Selvarajah, R. Gandhi, C.J. Emery, S. Tesfaye Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor Diabetes Care 33 2010 128 130
104. P. Mukhopadhyay, M. Rajesh, B. Horvath, S. Batkai, O. Park, G. Tanchian, R.Y. Gao, V. Patel, D.A. Wink, L. Liaudet, G. Hasko, R. Mechoulam, P. Pacher Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death Free Radic Biol Med 50 2011 1368 1381